Ethosuximide

Mechanism

Chemical and Commercial Profile

Common trade names: Zarontin, Ethosuximide Inibsa.
Group: First generation antiepileptic, succinimide derivative.

Mechanism of Action

Ethosuximide acts by specific, high-affinity blockade of low-threshold T-type calcium channels in neurons of the thalamocortical relay nucleus. By suppressing these low-threshold oscillatory currents, it interrupts the synchronous spike-wave discharge pacemaker at 3 Hz, characteristic of the electroencephalogram of absence seizures.

Pharmacokinetics

Pharmacokinetics

• Absorption: Rapid and almost complete orally, with a bioavailability close to 100%. The plasma peak is reached 3-7 hours after taking.
• Distribution: It practically does not bind to plasma proteins (0-5%), reducing interactions by displacement. Its volume of distribution is 0.7 L/kg, distributing it uniformly in total body water.
• Metabolism: Hepatic through oxidative hydroxylation catalyzed mainly by the CYP3A4 isoenzyme (80%) and the CYP2E1 isoenzyme. It generates four inactive metabolites.
• Excretion: Renal in the form of a metabolite conjugated with glucuronic acid (80%) and 20% in unaltered form.
• Half-life (t_1/2): Prolonged: 40-50 hours in adults; 30-35 hours in children and adolescents due to greater metabolic clearance.

Indicators and dose

Indications

• Typical childhood and youth absence crises (Pequeño Mal) of first choice.
• Atypical absence seizures (as adjuvant therapy).

Dosage and Settings

• Pediatric Population (3-6 years): Start with 250 mg/day (in a single dose); increase 250 mg/day every 4-7 days until clinical response is obtained. Common maintenance range: 15-30 mg/kg/day.
• Adult Population and Children >6 years: Start with 500 mg/day; increase from 250 mg to 250 mg weekly until reaching a common dose of 1000-1500 mg/day (divided into two doses).
• Target Plasma Range (Monitoring): 40-100 mcg/mL.
• Renal / Liver Failure: Not recommended in severe renal failure (Cl_Cr < 30 ml/min) or Child-Pugh B/C liver disease; If its use is essential, it requires rigorous analytical monitoring.

Security

Contraindications

• Hypersensitivity to succinimides.
• Do not use in concomitant generalized tonic-clonic seizures unless associated with another AED (it may exacerbate them reflexively).

Adverse Effects (ADR)

Children's Digestive Tolerance

The most common dose-limiting adverse effect at the beginning of treatment with ethosuximide in pediatric age is gastrointestinal intolerance, characterized by diffuse cramping abdominal pain, nausea, vomiting and anorexia. These symptoms are dependent on the dose and the plasma peak. They are controlled by a slow escalation regimen and by administering the daily dose divided into two or three doses with food.

• CNS: Tension headache, profound lethargy, dizziness, vivid nocturnal nightmares, paradoxical psychomotor agitation, sudden onset hiccups.
• Hematological (Rare but serious): Severe reversible leukopenia, idiopathic aplastic anemia, autoimmune thrombocytopenia.
• Immunological / Systemic: Drug-induced systemic lupus erythematosus syndrome, erythema multiforme, Stevens-Johnson syndrome.

Clinical Interactions

• With Valproic Acid: Coadministration with valproic acid decreases the clearance of ethosuximide by inhibiting hepatic hydroxylation, increasing its plasma concentrations by 15-25%. Requires analytical monitoring of both drugs.
• With carbamazepine and phenytoin: These enzyme inducers significantly reduce the serum concentration of ethosuximide by 30-40%.

Pregnancy and Breastfeeding

FDA Category: C. It is associated with a slight increase in fetal skeletal and cardiac anomalies in the first trimester. The risk/benefit ratio must be assessed against the appearance of absence status in the mother. Supplementation with folic acid essential. Breastfeeding: Relatively contraindicated. High milk excretion with infantile levels of up to 50-90% of maternal levels; high risk of sedation and irritability in the neonate.